Anaxsys Technology Ltd Lung Cancer Screening Device

肺癌是男性癌症死亡的主要原因，也是全球女性癌症死亡的第二大原因。据英国癌症协会报道，2011年英国有43,463人被诊断患有肺癌，2012年有35,371人死亡。肺癌的主要原因是吸烟，其他原因包括职业性接触致癌物质，如石棉。5年生存率为16%，主要是因为目前没有初级保健的筛查工具。Anaxsys开发了一种新型传感器，已被证明可以检测哮喘和COPD临床研究。对COPD患者的早期研究表明，肺癌和喉肿瘤也可以用这种传感器检测到，该传感器测量呼吸曲线。因此，Anaxsys正在开发一种安全、廉价的床旁筛查设备，可供全科医生在COPD专科诊所定期筛查COPD患者和吸烟者。这项检查将为全科医生提供足够的信息，以区分哪些患者应该在二级护理呼吸科接受诊断检查。肺癌的早期诊断将允许在肿瘤转移和扩散之前手术切除肿瘤。本项目的目的是通过市场调查确定全科医生是否需要肺癌筛查设备，以帮助他们识别那些应该在二级护理呼吸诊断诊所接受调查的COPD患者和吸烟者。该研究旨在了解肺癌和呼吸道癌症诊断的相关问题，以及提高当前5年生存率所需的措施。将与COPD诊所的全科医生及其专科护士进行访谈，以确定他们是否认为需要初级保健筛查工具。将与患者进行访谈，并获得有关设备的反馈。还将与药房连锁店进行访谈，确定是否有一个地方forsuch设备在这些业务.

Lung Cancer is the leading cause of cancer deaths in men and the second leading cause ofcancer deaths in women worldwide. Cancer UK reported that 43,463 people in the UK werediagnosed with lung cancer in 2011 and there were 35,371 deaths in 2012. The leading causeof lung cancer is smoking and other causes include occupational exposure to carcinogens suchas asbestos. The 5 year survival rate is 16%, largely because there is currently no screeningtool for primary care.Anaxsys has developed a novel sensor that has been shown to detect asthma and COPD inclinical studies. Early studies in COPD patients have shown that lung cancer and laryngealtumours can also be detected with this sensor, that measures breath profiles. Hence Anaxsys isdeveloping a safe, inexpensive point of care screening device that can be used by GPs toregularly screen COPD patients and smokers at their specialist COPD clinics. This test willprovide GPs with sufficient information to distinguish those patients who should be referredfor diagnostic tests at secondary care respiratory unit. Early diagnosis of lung cancer willallow surgical removal of tumours before they metastasise and spread.The objective of this project is to establish through market research whether GPs see a needfor a lung cancer screening device that can help them identify those COPD patients andsmokers who should be referred for investigation at a secondary care respiratory diagnosticclinic. The study seeks to understand the issues surrounding diagnosis of lung and respiratorytract cancers and what is required to improve the current 5 year survival rates.GPs with COPD clinics in their practices and their specialist nurses will be interviewed toestablish whether they see a need for a primary care screening tool.Interviews will be held with patients and feedback obtained on the device.Interviews will also be held with Pharmacy chains to establish whether there is a place forsuch a device in these businesses.